The Role of the Community Pharmacist in Managing Long-Acting Reversible Contraception

,
Pharmacy Times, February 2016 Autoimmune Disorders, Volume 82, Issue 2

This Continuing Education activity is supported by an educational grant from Teva Pharmaceuticals and Merck Sharp & Dohme Corp.

This activity is supported by an educational grant from Teva Pharmaceuticals and Merck Sharp & Dohme Corp.

The Role of the Community Pharmacist in Managing Long-Acting Reversible Contraception

Faculty

Andrea R. Gauld, PharmD, BCACP, BCPS

Assistant Professor

Department of Clinical and Administrative Sciences

Notre Dame of Maryland University, School of Pharmacy

Baltimore, Maryland

Jeannette Y. Wick, RPh, MBA, FASCP

Freelance Medical Writer

Arlington, Virginia

Visiting Professor

University of Connecticut School of Pharmacy

Storrs, Connecticut

Educational Objectives

After completing this continuing education program, the participant will be able to:

  • Explain the various types of hormonal and nonhormonal long-acting reversible contraception (LARC)
  • Evaluate the efficacy and safety of LARC therapy
  • Illustrate the role of the community pharmacist in identifying appropriate patients for LARC and managing concomitant drug therapy

Target audience: Retail P

harmacists

Type of activity: Application

Release date: February 8, 2016

Expiration date: February 8, 2017

Estimated time to complete activity: 2.0 hours

Fee: Free

Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-16-007-H01-P. The activity is available for CE credit through February 8, 2018.